Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 4/20 | 0.41 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19421443 | 0.81 | HSP90AA1 (0.44) | PARP1CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL24775490 | 0.76 | DRD2 (0.46) | PARP1DRD2CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL27111350 | 0.76 | DRD2 (0.46) | PARP1DRD2CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL14213446 | 0.75 | CHRNB2 (0.59) | PARP1CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL12609019 | 0.75 | CHRNB2 (0.59) | PARP1CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL2603280 | 0.75 | CHRNB2 (0.59) | PARP1CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL26546843 | 0.74 | CXCR4 (0.45) | PARP1DRD2OPRM1 | |
| SCHEMBL19862561 | 0.74 | PARP1 (0.43) | PARP1CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL2603327 | 0.74 | PARP1 (0.43) | PARP1CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL14213467 | 0.74 | PARP1 (0.40) | PARP1CHRNB2CHRNB4CHRNA3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402915-A1 | BCL-2 INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2022-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402915-A1 | BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L2 | PARP1 392/4885DRD2 4268/4885CHRNB2 4503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.